SYRACUSE, N.Y.–Repair Biotechnologies, Inc. announced today $2.15 million in seed venture funding, to accelerate the preclinical development of its pipeline of drugs targeting thymus regeneration, cancer, and atherosclerosis.

The $2.15 million in funding was led by Jim Mellon, the billionaire investor and Chairman of Juvenescence Ltd. Also participating in the round are Emerging Longevity Ventures, Thynk Capital, and SENS Research Foundation.

“We are committed to developing treatments for the root causes of aging and its associated diseases through the damage repair approach,” said Reason, co-founder and CEO. “With this funding round, we will be able to further develop our therapies and validate them in animal models, bringing them closer to the clinic and patients.”

The thymus gland is vital to the adaptive immune system, but with age, the thymus shrinks, leading to a decreased immune cell production and a compromised immune system. Repair Biotechnologies is developing a therapy with the aim of reverting this atrophy of the thymus, which the company believes can be an effective treatment against some forms of cancer.

Repair Biotechnologies’ second major project relates to atherosclerosis, which is caused by the accumulation of intracellular waste in arteries. While present therapies focus on reducing cholesterol, Repair Biotechnologies has licensed a technology to make the macrophage cells responsible for repairing arteries resilient to excess cholesterol, and thus able to repair atherosclerotic damage.

“SENS Research Foundation was founded to push forward proof-of-concept work demonstrating the validity of the SENS paradigm to the point at which people can actually do something with it. Now we’re seeing some of these technologies getting the recognition from investors that they deserve, which in turn is driving critical growth in the private-sector side of the field,” said Aubrey de Grey, co-founder and Chief Science Officer of SENS Research Foundation. “I’m thrilled to see Repair Biotechnologies taking things in this area to the next level.”

About Repair Biotechnologies:

Repair Biotechnologies, Inc. is a biotechnology company with the mission to develop and bring to the clinic therapies that significantly improve human healthspan through targeting the causes of age-related diseases and aging itself. Founded in 2018, Repair Biotechnologies is developing therapies with the goals of regenerating the thymus, treating cancer, and reversing atherosclerosis.

www.repairbiotechnologies.com

Contacts

Bill Cherman

bill@repairbiotechnologies.com

+1 415-212-6950

—